학술논문
Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant
Document Type
article
Author
Tarek H. Mouhieddine; Adam S. Sperling; Robert Redd; Jihye Park; Matthew Leventhal; Christopher J. Gibson; Salomon Manier; Amin H. Nassar; Marzia Capelletti; Daisy Huynh; Mark Bustoros; Romanos Sklavenitis-Pistofidis; Sabrin Tahri; Kalvis Hornburg; Henry Dumke; Muhieddine M. Itani; Cody J. Boehner; Chia-Jen Liu; Saud H. AlDubayan; Brendan Reardon; Eliezer M. Van Allen; Jonathan J. Keats; Chip Stewart; Shaadi Mehr; Daniel Auclair; Robert L. Schlossman; Nikhil C. Munshi; Kenneth C. Anderson; David P. Steensma; Jacob P. Laubach; Paul G. Richardson; Jerome Ritz; Benjamin L. Ebert; Robert J. Soiffer; Lorenzo Trippa; Gad Getz; Donna S. Neuberg; Irene M. Ghobrial
Source
Nature Communications, Vol 11, Iss 1, Pp 1-9 (2020)
Subject
Language
English
ISSN
2041-1723
Abstract
Multiple myeloma (MM) is treated with induction chemotherapy, autologous stem cell transplant (ASCT) and long-term immunomodulatory drug (IMiD) maintenance. Here, the authors show that the presence of clonal haematopoiesis of indeterminate potential (CHIP) at time of ASCT is associated with adverse outcomes in MM patients.